Celldex Therapeutics Inc.
CLDX | NASDAQ
$34.50
-$3.39 (-8.95%)
Sep 22, 2026, 1:49 PM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 112K | 820K | 1.5M | 2.6M | 5.79M | 7.56M | 7.02M | 9.98M | 8.3M | 6.07M | 6.88M | 4.37M | 3.26M | 3.15M | 2.36M | 1.08M | 824K | 4.14M | 4.65M | 8.1M | 8.62M | 5.37M |
Cost of Revenue | 63.79M | 117.98M | 169.74M | 170.56M | 152.89M | 99.49M | 47.65M | 77.26M | 32.77M | 58.22M | 84.24M | 76.72M | 97.52M | 92M | 82.26M | 74.04M | 66.02M | 57.65M | 53.31M | 49.06M | 46.21M | 43.56M |
Gross Profit | -63.7M | -117.16M | -168.24M | -167.96M | -147.1M | -91.93M | -40.63M | -67.29M | -24.46M | -52.15M | -77.36M | -72.35M | -94.27M | -88.85M | -79.9M | -72.96M | -65.2M | -53.51M | -48.66M | -40.96M | -37.59M | -38.18M |
Operating Income | -245.24M | -309.1M | -287.4M | -256.24M | -234.75M | -217.21M | -195.08M | -186.68M | -175.79M | -162.68M | -154.54M | -134.8M | -121.26M | -124.45M | -115.23M | -107.69M | -100.82M | -77.86M | -71.24M | -75.68M | -69.2M | -67.13M |
Interest Income | 18.16M | 25.42M | 28.61M | 31.71M | 35.14M | 38.36M | 37.22M | 32.6M | 25.58M | 17.8M | 13.11M | 10.19M | 8.12M | 5.81M | 2.91M | 1.7M | 936K | 611K | 505K | 2.26M | 2.23M | 2.27M |
Pretax Income | -300.59M | -283.69M | -258.8M | -224.53M | -199.61M | -178.85M | -157.86M | -154.08M | -150.22M | -144.88M | -141.43M | -124.61M | -113.13M | -118.64M | -112.33M | -105.99M | -99.88M | -77.25M | -70.74M | -73.43M | -66.97M | -64.86M |
Net Income | -300.59M | -283.69M | -258.8M | -224.53M | -199.61M | -178.85M | -157.86M | -154.08M | -150.22M | -144.88M | -141.43M | -124.61M | -113.13M | -118.64M | -112.33M | -105.99M | -99.65M | -77.02M | -70.51M | -72.26M | -66.04M | -63.69M |
Selling & General & Admin | 47.14M | 44.43M | 43.8M | 42.16M | 41.53M | 40.27M | 38.55M | 37.12M | 35.28M | 33.38M | 30.91M | 28.68M | 26.99M | 26.92M | 27.2M | 26.84M | 26.13M | 23.28M | 20.49M | 17.87M | 15.69M | 14.91M |
Research & Development | 211.3M | 265.49M | 245.1M | 215.86M | 198.19M | 182.89M | 161.16M | 145.47M | 134.74M | 122.1M | 118.01M | 110.48M | 97.52M | 92M | 82.26M | 74.04M | 69.52M | 61.15M | 56.81M | 70.56M | 64.21M | 65.06M |
Other Expenses | 3.75M | -117.98M | -169.74M | -169.74M | -152.07M | -97.88M | -45.26M | -63.19M | -18.69M | -44.95M | -71.74M | -76.72M | -97.52M | -83.33M | -74.12M | -66.14M | -60.03M | -60.07M | -54.72M | -53.7M | -48.29M | -51.03M |
Operating Expenses | 262.19M | 191.94M | 119.16M | 88.28M | 87.65M | 125.28M | 154.44M | 119.39M | 151.33M | 110.53M | 77.18M | 62.45M | 26.99M | 35.6M | 35.33M | 34.73M | 35.62M | 24.36M | 22.58M | 34.73M | 31.61M | 28.94M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 3.11M | 3.11M | 3.11M | 3.11M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 245.33M | 309.92M | 288.9M | 258.84M | 240.54M | 224.77M | 202.1M | 196.65M | 184.09M | 168.75M | 161.42M | 139.16M | 124.51M | 127.6M | 117.59M | 108.77M | 101.64M | 82M | 75.9M | 83.79M | 77.82M | 72.5M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -227K | -227K | -227K | -1.17M | -939K | -1.17M |
Shares Outstanding (Basic) | 77.84M | 66.57M | 66.5M | 66.42M | 66.39M | 66.38M | 66.35M | 66.29M | 66.02M | 58.87M | 52.03M | 47.26M | 47.25M | 47.21M | 47.13M | 46.92M | 46.76M | 46.74M | 46.58M | 45.45M | 39.33M | 39.38M |
Shares Outstanding (Diluted) | 77.84M | 66.57M | 66.5M | 66.42M | 66.39M | 66.38M | 66.35M | 66.29M | 66.02M | 58.87M | 52.03M | 47.26M | 47.25M | 47.21M | 47.13M | 46.92M | 46.76M | 46.74M | 46.69M | 45.45M | 39.62M | 39.61M |
EPS (Basic) | -4.36 | -4.27 | -3.90 | -3.38 | -3.01 | -2.70 | -2.45 | -2.57 | -2.74 | -2.85 | -2.91 | -2.64 | -2.40 | -2.52 | -2.39 | -2.26 | -2.14 | -1.71 | -1.64 | -1.76 | -1.67 | -1.83 |
EPS (Diluted) | -4.36 | -4.27 | -3.90 | -3.38 | -3.01 | -2.70 | -2.45 | -2.57 | -2.74 | -2.85 | -2.91 | -2.64 | -2.40 | -2.52 | -2.39 | -2.26 | -2.14 | -1.71 | -1.64 | -1.76 | -1.67 | -1.83 |
EBITDA | -224.6M | -280.32M | -255.42M | -221.15M | -196.26M | -175.58M | -154.69M | -142.78M | -138.94M | -133.64M | -130.24M | -121.69M | -110.31M | -107.54M | -101.89M | -95.88M | -88.24M | -73.68M | -66.08M | -55.78M | -50.13M | -49.56M |
EBIT | -227.09M | -283.69M | -258.8M | -224.53M | -199.61M | -178.85M | -157.86M | -145.9M | -142.04M | -136.7M | -133.25M | -124.61M | -113.13M | -110.35M | -104.79M | -98.88M | -91.33M | -76.79M | -69.15M | -58.83M | -53.28M | -53.1M |
Depreciation & Amortization | 2.49M | 3.37M | 3.38M | 3.38M | 3.35M | 3.27M | 3.18M | 3.12M | 3.1M | 3.06M | 3.01M | 2.92M | 2.83M | 2.81M | 2.9M | 3M | 3.08M | 3.1M | 3.07M | 3.05M | 3.15M | 3.54M |
Add to Watchlist
Select watchlists to add or remove CLDX